返回 
加入收藏
匹多莫德联合头孢曲松治疗老年支气管肺炎的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 匹多莫德联合头孢曲松治疗老年支气管肺炎的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察匹多莫德联合头孢曲松治疗老年支气管肺炎的疗效和安全性。方法：164例老年支气管肺炎患者随机分为观察组（82例）和对照组（82例）。在常规治疗的基础上，对照组患者给予注射用头孢曲松钠 2 g，加入0.9％氯化钠注射液100 mL中，静脉滴注，每日1次；观察组患者在对照组治疗的基础上给予匹多莫德口服液7 mL，口服，每日2次。两组均治疗2周。观察两组患者的临床疗效、退热时间、咳嗽憋喘消失时间、胸片好转时间、平均住院时间和治疗前后血清肿瘤坏死因子α（TNF-α）、白细胞介素6 （IL-6）、超敏C反应蛋白（hs-CRP）、免疫球蛋白G（IgG）、IgA、IgM水平及不良反应发生情况。结果：观察组患者总有效率（95.12％）显著高于对照组（81.71％）；退热时间、咳嗽憋喘消失时间、胸片好转时间、平均住院时间均显著短于对照组，差异均有统计学意义（P＜0.05）。治疗后，两组患者血清TNF-α、IL-6、hs-CRP、IgM水平均显著低于同组治疗前，且观察组显著低于对照组；两组患者IgG、IgA水平均显著高于同组治疗前，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：匹多莫德联合头孢曲松治疗老年支气管肺炎疗效显著，可改善患者临床症状，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of pidotimod combined with ceftriaxone sodium in the treatment of elderly bronchopneumonia. METHODS： A total of 164 elderly patients with bronchopneumonia were randomly divided into observation group （82 cases） and control group （82 cases）. Based on routine treatment， control group was given Ceftriaxone sodium for injection 2 g added into 0.9％ Sodium chloride solution 100 mL intravenously， once a day. Observation group was additionally given Pidotimod oral solution 7 mL， twice a day， on the basis of control group. Both group were treated for 2 weeks. Clinical efficacy， defervescence time， cough and wheezing disappearance time， chest radiograph improvement time and average hospitalization time were observed in 2 groups. The serum levels of TNF-α， IL-6， hs-CRP， IgG， IgA and IgM before and after treatment， the occurrence of ADR were observed. RESULTS： Total response rate of observation group （95.12％） was significantly higher than that of control group （81.71％）； and defervescence time， cough and wheezing disappearance time， chest radiograph improvement time and average hospitalization time were significantly shorter than control group， with statistical significance （P＜0.05）. After treatment， serum levels of TNF-α， IL-6， hs-CRP and IgM in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group； the levels of IgG and IgA in 2 groups were significantly higher than before treatment， and the observation group was significantly higher than the control group， with statistical significance（P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Pidotimod combined with ceftriaxone shows significant therapeutic efficacy for elderly bronchopneumonia and improve clinical symptoms without increasing the occurrence of ADR. |
| 期刊： | 2017年第28卷第30期 |
| 作者： | 徐慧，李媛媛 |
| AUTHORS： | XU Hui，LI Yuanyuan |
| 关键字： | 老年支气管肺炎；匹多莫德；头孢曲松；疗效；安全性 |
| KEYWORDS： | Elderly bronchopneumonia； Pidotimod； Ceftriaxone； Therapeutic efficacy； Safety |
| 阅读数： | 285 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
